Skip to main content
Quest Diagnostics

Establishing a Common Lexicon for Circulating Tumor DNA Analysis and Molecular Residual Disease: Insights From the BLOODPAC Consortium

Establishing a Common Lexicon for Circulating Tumor DNA Analysis and Molecular Residual Disease: Insights From the BLOODPAC Consortium

Authors: Hadd AG, Silvestro A, McKelvey BA, Baden J, Bormann Chung C, Brown B, Cruz-Guilloty F, Godsey J, Jones G, Lin CJ, Lopez Ramos D, Norton D, Palomares MR, Pena C, Rich T, Rodriguez A, Stewart M, Merino Vega D, Leiman LC

Citation: Clin Transl Sci. 2025 Mar;18(3):e70185. doi: 10.1111/cts.70185.

Specialties: Oncology

Related content

Publication
Budget Impact Analysis of Circulating Tumor DNA Testing for Colon Cancer in Commercial Health and Medicare Advantage Plans
Test FAQ
Haystack MRD Testing
On-Demand Webinar
Precision Medicine: Your Role in Advancing the Future of Cancer Care
Publication
NGS defined measurable residual disease MRD after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia
Conference Presentation
Budget Impact of Circulating Tumor DNA Testing for Colon Cancer to Healthcare Insurers
Conference Presentation
Analytical Validation of the Haystack MRD Assay for the detection of extremely low ctDNA in Solid Tumor Patients

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.